#USA #Boston #oncology research #Leerink Partners #Asthika Goonewardene

Leerink Partners Expands Its Oncology Research Team

In the ongoing effort to bolster its healthcare research division, Leerink Partners has announced the addition of Asthika Goonewardene as the Senior Managing Director and Senior Research Analyst focusing on oncology. This strategic move was made public on June 22, 2026, and it reflects the investment bank's commitment to understanding and serving the intricate world of cancer therapeutics and emerging biotechnologies.

Mr. Goonewardene, who will be operating from the Miami office, is set to report directly to Jim Kelly, the Director of Equity Research at Leerink Partners. His arrival is particularly noted for the depth of industry knowledge he brings, a result of nearly two decades of in-depth analysis in the biotechnology arena. His expertise extends across critical fields such as cancer therapeutics, immuno-oncology, and cell therapy, making him a valuable asset for the firm as it seeks to deepen its research capabilities.

Before joining Leerink Partners, Goonewardene served as the Managing Director and Senior Biotechnology Analyst at Truist Securities, where his contributions were instrumental in shaping the firm's insights into the biotechnology landscape. Moreover, his tenure at Bloomberg Intelligence saw him lead coverage of the global biotechnology sector, further establishing his credentials as a leading analyst in the field.

Jim Kelly endorsed Goonewardene's appointment by highlighting the importance of his track record in identifying emerging trends within oncology and his unique perspective on the sector. "Asthika is a highly respected biotechnology analyst with a strong track record of identifying emerging trends and providing differentiated insights across the oncology landscape," Kelly stated. He believes that Goonewardene's extensive understanding and connections will significantly bolster the firm’s research platform and enhance the value offered to both institutional investors and corporate clients.

In his new position, Goonewardene's responsibilities will predominantly revolve around publicly traded oncology firms and cutting-edge therapeutic technologies, providing exhaustive research and analytical insights that reflect the swift evolution occurring in one of healthcare's most dynamic fields. This is crucial as advancements in cancer treatments continue to emerge at an unprecedented pace.

Upon his joining the firm, Goonewardene expressed enthusiasm about contributing to an already exceptional research team. He remarked, "Leerink Partners has built the industry's premier healthcare research platform and a reputation for delivering high-quality, differentiated insights to investors." He is eager to assist clients in navigating what is being recognized as one of the most innovative periods in oncology history.

Leerink Partners, historically recognized for its specialized services within the healthcare investment banking sector, expresses a clear focus on continued excellence and innovative solutions. With a legacy of advising on substantial financial transactions, the firm has established a reputation grounded in expertise and remarkable client service.

The firm’s impressive achievements include advising on transactions amounting to $85 billion and aiding its clients in raising over $220 billion. Such accomplishments position Leerink as a pivotal partner for healthcare companies and their investors, especially in light of advancing medical technologies and therapeutic techniques.

To discover more about Leerink Partners and the insights they offer, interested parties are invited to visit their official website at Leerink Partners. This move to strengthen their oncology research capabilities underscores the firm’s intent to remain at the forefront of healthcare investment banking, delivering the insights necessary for informed decision-making in an ever-evolving market.